Protalix BioTherapeutics, Inc. (PLX)
NYSE: PLX · Biological Products, (No Diagnostic Substances) · Hackensack, NJ · filing with the SEC since 1996
Grade5.4
◀ Past 4.9● Present 7.0▶ Future 3.8
Who owns Protalix BioTherapeutics, Inc.
As filed with the SECHolders of 5% or more
2
HOLD Alapkezelo Zrt. holds 5.2% of Common Shares, as its SCHEDULE 13G filed Oct 15, 2026 says.
Directors and officers
10
report now, of 18 people on the record since 2007. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
HOLD Alapkezelo Zrt.
SCHEDULE 13G · filed Oct 15, 2026 · Common Shares
Blackrock, Inc.
SCHEDULE 13G · filed Jul 29, 2026 · Common Stock
MAK Capital Fund LP
SCHEDULE 13G/A · filed Mar 30, 2026 · Common Stock, $0.001 par value per share · reported falling below 5%, from 5.8% in Mar 4, 2026
What PLX reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 17, 2025.
Insider tradesForm 4
1sales
1purchases
0sales on a scheduled plan
1people selling
$0sold, in dollars
$100,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2025 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 21 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Bashan Dror | PRESIDENT AND CEO | 0 | $0 | 0 | 1 | $100,000 |
| Bar-Shalev Amos | director | 1 | $0 | 0 | 0 | $0 |